Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech Scientific (OTCPK:LFTSF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
LifeTech Scientific Forward PE Ratio Related Terms
LifeTech Scientific Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific Forward PE Ratio Chart
LifeTech Scientific Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
17.96
25.94
LifeTech Scientific Semi-Annual Data
2024-12
2025-06
2025-12
Forward PE Ratio
17.96
25.94
25.94
LFTSF vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, LifeTech Scientific's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
LifeTech Scientific (LFTSF) has a Forward PE Ratio of 25.94 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on LifeTech Scientific and its competitors. According to the industry distribution chart, LifeTech Scientific ranks #214 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 54.6%.
Is LifeTech Scientific's Forward PE Ratio too high?
LifeTech Scientific's current Forward PE Ratio is 25.94. The Medical Devices & Instruments industry median Forward PE Ratio is 19.19. LifeTech Scientific's value of 25.94 is 35.2% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #214 out of 392 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #214 out of 392 companies for Forward PE Ratio. This places LifeTech Scientific in the lower half of its industry. The industry median Forward PE Ratio is 19.19. LifeTech Scientific's value of 25.94 is 35.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.19, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Forward PE Ratio of 25.94 is 35.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Forward PE Ratio is 25.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current Forward PE Ratio of 25.94. The stock's GF Value™ is $0.35, compared to a current price of $0.23 — trading 33.3% below its estimated fair value. The current Forward PE Ratio is 25.94 and 35.2% above the Medical Devices & Instruments industry median of 19.19. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current Forward PE Ratio is 25.94 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 33.3% below its estimated GF Value™ of $0.35.
Key valuation signals for LFTSF:
Forward PE Ratio: 25.94
GF Value™: $0.35 vs. price of $0.23 (33.3% below fair value)
Industry Position: 35.2% above the Medical Devices & Instruments median (#214 of 392)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score
Get the complete analysis for LFTSF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
